GeneDx has upgraded its 2025 revenue guidance following robust second-quarter results, driven by a 49% year-over-year revenue increase. The genetic diagnostics firm saw whole-exome and whole-genome testing revenues jump significantly, supported by improved reimbursement rates. The company plans to target the general pediatrics market, leveraging new American Academy of Pediatrics guidelines recommending sequencing for intellectual and developmental disabilities, to further expand growth. The management aims to raise awareness among pediatricians and update payor medical policies to align with guidelines, while maintaining sustained volume growth in genomic testing services.